MAPT and Alzheimer disease: As with Aß, there have been numerous reports that APOE4 carriers possess higher levels of tau pathology than non-carriers prior to AD onset, although this effect on preclinical tau pathology does not seem to be nearly as robust as it is with APOE4’s effects on preclinical Aß levels.